Cytocom, Inc.
CBLI · NASDAQ
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.03 | 0.09 | 0.05 | -0.02 |
| FCF Yield | -5.55% | -39.18% | -40.69% | -14.74% |
| EV / EBITDA | -17.10 | -2.16 | -2.17 | -4.20 |
| Quality | ||||
| ROIC | -58.96% | -210.14% | -171.55% | -42.98% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.99 | 1.01 | 1.28 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -38.64% | -17.02% | -31.35% | -10.40% |
| Free Cash Flow Growth | 10.96% | 42.58% | 29.85% | -31.01% |
| Safety | ||||
| Net Debt / EBITDA | 0.82 | 0.43 | 1.01 | 0.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 15.98 | 124.20 | 80.76 | 103.87 |